Science & Innovation
252 views | +0 today
Your new post is loading...
Your new post is loading...
Scooped by Philippe Smelty
Scoop.it!

Des ultrasons pour diagnostiquer les lésions cérébrales

Des ultrasons pour diagnostiquer les lésions cérébrales | Science & Innovation | Scoop.it
+VIDEO // Arminas Ragauskas a conçu des appareils de mesure à ultrasons qui diagnostiquent rapidement le
more...
No comment yet.
Scooped by Philippe Smelty
Scoop.it!

Ces créatures uniques sont nées dans une grotte restée scellée pendant 5 millions d’années

Ces créatures uniques sont nées dans une grotte restée scellée pendant 5 millions d’années | Science & Innovation | Scoop.it
Ulyces est une maison d’édition numérique dédiée au journalisme narratif.
more...
No comment yet.
Rescooped by Philippe Smelty from Pharma Biotech Industry Review (Krishan Maggon)
Scoop.it!

Sanofi launches $9.3 blillion fight for U.S. cancer firm Medivation

Sanofi launches $9.3 blillion fight for U.S. cancer firm Medivation | Science & Innovation | Scoop.it

French drugmaker Sanofi went public with a $9.3 billion offer to buy Medivation on Thursday, setting up what could be a lengthy takeover battle after the U.S. cancer firm rebuffed its approaches.


Sanofi could now face a prolonged takeover fight with other players potentially getting involved, including Japan's Astellas Pharma, Medivation's partner on its prostate cancer drug Xtandi. Britain's AstraZeneca has also been reported to have looked at Medivation.




Via Krishan Maggon
more...
Krishan Maggon 's curator insight, April 29, 4:22 AM
Astellas markets Medivation drug XTANDI® (enzalutamide) for prostate cancer and 2015 sales were $1.2 billion and projected 2016 sales at $1.5 billion. 

Enzalutamide currently is approved in the United States, Europe and numerous other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC), and is being further developed* for earlier stages of prostate cancer, advanced breast cancer and hepatocellular carcinoma. 

Talazoparib (MDV3800), an orally available poly-ADP ribose polymerase, or PARP, inhibitor, is  currently is in a Phase 3 clinical trial for the treatment of patients with gBRCA mutated breast cancer (i.e., advanced breast cancer in patients whose BRCA genes contain germline mutations).  Medivation has acquired worldwide rights to talazoparib (MDV3800), an orally-available poly ADP ribose polymerase (PARP) inhibitor, from BioMarin Pharma.
Our third asset is pidilizumab (MDV9300), an antibody with immune-mediated anti-tumor effects, which we licensed exclusive worldwide rights from CureTech, Ltd., in 2014. We plan to develop pidilizumab in diffuse large B-cell lymphoma and other hematologic malignancies, such as multiple myeloma. 

A fourth asset, a novel small molecule inhibitor of the sterol regulatory element-binding protein, or SREBP, pathway which we refer to as MDV4463. MDV4463 is currently in a Phase 1 trial in healthy volunteers.


Rescooped by Philippe Smelty from Actualité des laboratoires du CNRS en Midi-Pyrénées
Scoop.it!

CRCA - Un organisme unicellulaire capable d'apprendre

CRCA - Un organisme unicellulaire capable d'apprendre | Science & Innovation | Scoop.it
Pour la première fois, des chercheurs viennent de démontrer qu'un organisme dépourvu de système nerveux est capable d'apprentissage. Une équipe du Centre de recherches sur la cognition animale (CNRS/Université Toulouse III – Paul Sabatier) a réussi à démontrer qu'un organisme unicellulaire, le protiste Physarum polycephalum, est capable d'une forme d'apprentissage nommée habituation. Cette découverte permet d'éclairer l'origine de la capacité d'apprentissage durant l'évolution, avant même l'apparition du système nerveux et du cerveau. Elle pourrait également amener à s'interroger sur la capacité d'apprentissage d'autres organismes extrêmement simples comme les virus et les bactéries. Ces résultats sont publiés dans la revue Proceedings of the Royal Society B le 27 avril 2016.

Via Le CNRS en Midi-Pyrénées
more...
Le CNRS en Midi-Pyrénées's curator insight, April 27, 5:26 AM
© Audrey Dussutour (CNRS)

Le protiste Physarum polycephalum (diamètre : environ 10 centimètres), composé d'une unique cellule, cultivé en laboratoire sur un gel d'agar.


Suivez #CRCA et @INSB_CNRS
Scooped by Philippe Smelty
Scoop.it!

The World's Most Innovative Research Institutions | Reuters

The World's Most Innovative Research Institutions | Reuters | Science & Innovation | Scoop.it
weight: bold; padding: 3px; padding-left: 10px; font-size: 12px; padding-right: 5px;"REUTERS TOP 25(Reuters) - Silicon Valley’s hoodie-wearing tech entrepreneurs are the poster kids of innovation.
more...
No comment yet.
Scooped by Philippe Smelty
Scoop.it!

Sida : des anticorps capables d'éliminer les cellules infectées - Communiqués et dossiers de presse - CNRS

more...
No comment yet.
Scooped by Philippe Smelty
Scoop.it!

These Gamers Helped Create A Scientific Breakthrough About The Building Blocks Of Life

These Gamers Helped Create A Scientific Breakthrough About The Building Blocks Of Life | Science & Innovation | Scoop.it
Eterna is a game designed to let gamers help scientists figure out how to manipulate RNA. Now some of Eterna's players have become scientists...
more...
No comment yet.
Rescooped by Philippe Smelty from Amazing Science
Scoop.it!

Einstein’s Gravitational Waves Detected Originating from Merging Black Holes 1.3 Billion Years Ago

Einstein’s Gravitational Waves Detected Originating from Merging Black Holes 1.3 Billion Years Ago | Science & Innovation | Scoop.it
Today, scientists announced that, for the first time in history, gravitational waves have been detected.

Gravitational waves are ripples in spacetime throughout the universe. What’s truly remarkable about this discovery is that Albert Einstein predicted the existence of gravitational waves 100 years ago, but scientists have never been able to detect them, until now.

The discovery came out of the U.S. based Laser Interferometer Gravitational Wave Observatory (LIGO). The mission of LIGO was to directly measure gravitational waves. In order to do that, LIGO scientists needed to construct the most precise measuring device the world had ever seen.

The LIGO project, which began in 1992, was the largest scientific investment the National Science Foundation (NSF) has ever made.

At an NSF press conference this morning, LIGO Laboratory Executive Director, David Reitze, said “This was a scientific moon shot. And we did it – we landed on the moon.”

 

LIGO consists of two 4 kilometer (2.5 mile) tunnels located in Louisiana and the state of Washington. Because gravitational waves stretch space in one direction and compress space in the other, LIGO was designed to measure changes in length across large land distances. If they could detect a stretch of land in the LIGO tunnels in one direction and compression in the other, they could theoretically detect a gravitational wave.

 

The “ruler” that scientists used to measure these tunnel lengths was the speed of light. The speed of light is constant, so LIGO can determine the length of the tunnels by measuring the time it takes for a laser to bounce from one end of the tunnel to the other.

 

Gravitational waves are created when masses accelerate. Measured back on September 14th, 2015, the gravitational wave signal that the LIGO scientists detected matches the exact signal they’d expect from two merging black holes accelerating at half the speed of light.

 

Reitze explained that the black holes that created this gravitational wave merged 1.3 billion years ago. It took that long for the wave to travel to the Earth. Each of the black holes were 30 times the mass of the sun and were accelerating at half the speed of light when they collided into each other. The ability to measure gravitational waves will open up an entirely new window for astronomy. Reitze explained that this will enable scientists to look at the universe in a new way.

 


Via Dr. Stefan Gruenwald
more...
No comment yet.
Scooped by Philippe Smelty
Scoop.it!

Les textiles qui soignent - FUTUREMAG - ARTE

www.futuremag.fr Aujourd'hui, la mode soigne l'Homme grâce à des tissus toujours plus innovants. De la soie anti-microbienne qui protège notre peau au tissu ...
more...
No comment yet.
Scooped by Philippe Smelty
Scoop.it!

The Future of Jobs

The Future of Jobs | Science & Innovation | Scoop.it
Skills and jobs displacement will affect every industry and geographical region, but losses can be offset by job growth in key areas.
more...
No comment yet.
Rescooped by Philippe Smelty from Cancer Immunotherapy Review
Scoop.it!

Animation Tumour immunology and immunotherapy


Via Krishan Maggon
more...
Laurent LEVY's curator insight, October 2, 2015 12:56 PM

Superb animation 

Rescooped by Philippe Smelty from Alzheimer's Disease R&D Review
Scoop.it!

G-Force PD: a global initiative in coordinating stem cell-based dopamine treatments for Parkinson’s disease- Nature.com

G-Force PD: a global initiative in coordinating stem cell-based dopamine treatments for Parkinson’s disease- Nature.com | Science & Innovation | Scoop.it

Nature.com

Translating new cell-based therapies to the clinic for patients with neurodegenerative disorders is complex. It involves pre-clinical testing of the cellular product and discussions with several regulatory agencies, as well as ethical debates. In an attempt to support efforts around the world, we set up a global consortium that brings together the major funded teams working on developing a stem cell-derived neural transplantation therapy for Parkinson’s disease (PD). This consortium, G-Force PD, involves teams from Europe, USA, and Japan, and has already met on two occasions to discuss common problems, solutions, and the roadmap to the clinic. In this short review, we lay out the brief history and rationale for this initiative and discuss some of the issues that arose in our most recent meeting (May 2015) as we consider undertaking first-in-human clinical trials with stem cell-derived neurons for PD.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, September 25, 2015 10:37 AM

NPJ PARKINSON'S DISEASE | PERSPECTIVE OPEN

G-Force PD: a global initiative in coordinating stem cell-based dopamine treatments for Parkinson’s diseaseRoger A Barker, Lorenz Studer, Elena Cattaneo, Jun Takahashi & G-Force PD consortiumAffiliationsCorresponding authornpj Parkinson's Disease 1, Article number: 15017 (2015) doi:10.1038/npjparkd.2015.17
Rescooped by Philippe Smelty from Personalised medicine
Scoop.it!

The 6th Annual Personalized and Precision Medicine Conference 2014 Agenda

The 6th Annual Personalized and Precision Medicine Conference 2014 Agenda | Science & Innovation | Scoop.it
This is The 6th Annual Personalized and Precision Medicine Conference Agenda. The conference will be exploring the ways in which Personalized & Precision Medicine is reshaping healthcare. This conference brings together multiple stakeholders, including payers, molecular diagnostics companies, genome analysis/interpretation companies, clinicians and many others in order to provide attendees with a holistic view of the personalized medicine landscape.

Via Emma Pettengale
more...
No comment yet.
Scooped by Philippe Smelty
Scoop.it!

Conformal piezoelectric energy harvesting and storage from motions of the heart, lung, and diaphragm

Philippe Smelty's insight:
The Scientific article is here : http://m.pnas.org/content/111/5/1927.abstract
more...
No comment yet.
Scooped by Philippe Smelty
Scoop.it!

Bayer offre 62 milliards pour faire l'acquisition de Monsanto

Bayer offre 62 milliards pour faire l'acquisition de Monsanto | Science & Innovation | Scoop.it
Le groupe chimique et pharmaceutique allemand Bayer a fait une offre non sollicitée de 62 milliards de dollars américains pour acquérir le spécialiste américain des semences génétiquement modifiées Monsanto, afin de créer un leader mondial de l'agrochimie.
more...
No comment yet.
Rescooped by Philippe Smelty from LaLIST Veille Inist-CNRS
Scoop.it!

Le CNRS référencé dans trois classements mondiaux des organismes les plus innovants

Le CNRS référencé dans trois classements mondiaux des organismes les plus innovants | Science & Innovation | Scoop.it
"Le CNRS est classé à la 5e place  du nouveau classement de Thomson-Reuters des organismes publics  les plus innovants au monde. Il figure aussi dans le Top 100 des innovateurs mondiaux, toujour

Via LaLIST
more...
No comment yet.
Rescooped by Philippe Smelty from Smart Santé
Scoop.it!

The Emerging Influence of Digital Biomarkers on Healthcare

The Emerging Influence of Digital Biomarkers on Healthcare | Science & Innovation | Scoop.it

In healthcare, big data is only valuable when paired with a strong body of clinical evidence. Digital biomarkers are an opportunity to translate new data sources into informative, actionable insights.


Via CVSTENE
more...
CVSTENE's curator insight, April 24, 5:49 PM

Très bon rapport de Rock Health sur la place prise de plus en plus importante des technologies de santé connectée (type biomarqueur) dans la médecine.

 

Scooped by Philippe Smelty
Scoop.it!

L’Alliance ATHENA remet le rapport "Recherches sur les radicalisations" au MESR | Alliance Athéna \ alliance nationale des sciences humaines et sociales

more...
No comment yet.
Scooped by Philippe Smelty
Scoop.it!

Le secret des équipes les plus productives est simple: la gentillesse

Le secret des équipes les plus productives est simple: la gentillesse | Science & Innovation | Scoop.it
En 2012, Google a lancé le Projet Aristote, une étude dont le but était d'éclaircir un grand mystère managérial: qu'est-ce qui fait qu'une équipe de travail est efficace?
more...
No comment yet.
Rescooped by Philippe Smelty from Hepatitis C New Drugs Review
Scoop.it!

Scientific Advances in HIV and HCV To Be Examined Next Week at CROI 2016

Scientific Advances in HIV and HCV To Be Examined Next Week at CROI 2016 | Science & Innovation | Scoop.it

The 2016 Conference on Retroviruses and Opportunistic Infections (CROI) takes place next week in Boston, and AIDS.gov will be there.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, February 20, 3:44 AM

 

SCIENTIFIC ADVANCES IN HIV AND HCV TO BE EXAMINED NEXT WEEK AT CROI 2016
 
February 19, 2016 • 0 comments • By Miguel Gomez, Director, AIDS.gov, and Senior Communications Advisor, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services 

The 2016 Conference on Retroviruses and Opportunistic Infections (CROI)  takes place next week in Boston, and AIDS.gov will be there. 

Scooped by Philippe Smelty
Scoop.it!

Why @Microsoft is testing underwater data centers via @FastCoExist

Why @Microsoft is testing underwater data centers via @FastCoExist | Science & Innovation | Scoop.it
Philippe Smelty's insight:
The ocean is cold, dark, and awash in kinetic energy—which makes it surprisingly ideal for data centers.
more...
No comment yet.
Scooped by Philippe Smelty
Scoop.it!

Police train eagles to take down drones on sight (Wired UK)

Police train eagles to take down drones on sight (Wired UK) | Science & Innovation | Scoop.it
The Dutch National Police force has announced it will train eagles to bring down unmanned drones in the case of an emergency.
more...
No comment yet.
Rescooped by Philippe Smelty from Innovation Agro-activités et Bio-industries
Scoop.it!

Quand la Big Pharma rencontre le Big Data

Quand la Big Pharma rencontre le Big Data | Science & Innovation | Scoop.it
A l'instar du partenariat noué ce mois-ci entre Sanofi et Google, de plus en plus de passerelles existent entre les...

Via AgroParisTech DOC IST
more...
No comment yet.
Rescooped by Philippe Smelty from Pharma Biotech Industry Review (Krishan Maggon)
Scoop.it!

EC/EMA Approval for Praluent® (alirocumab, Sanofi, Regeneron) for Hypercholesterolemia in EU

EC/EMA Approval for Praluent® (alirocumab, Sanofi, Regeneron) for Hypercholesterolemia in EU | Science & Innovation | Scoop.it

Paris and Tarrytown, New York - September 28, 2015 - Sanofi and Regeneron Pharmaceuticals, Inc.announced today that the European Commission (EC) has granted marketing authorization for Praluent®(alirocumab) for the treatment of bad cholesterol, known as low-density lipoprotein (LDL) cholesterol, in certain adult patients with hypercholesterolemia. Praluent is the only EC-approved PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor that is available in two starting doses as a single 1-milliter (mL) injection (75 mg and 150 mg) once every two weeks, offering two levels of efficacy. Praluent will be available in a single-dose pre-filled pen that patients self-administer.

 

The EC marketing authorization is based on data from 10 pivotal Phase 3 ODYSSEY trials, including five placebo-controlled and five ezetimibe-controlled. The data showed consistent, robust reductions in LDL-cholesterol for Praluent compared to placebo or ezetimibe, when added to current standard-of-care, which included maximally-tolerated statins. All trials met their primary efficacy endpoint, demonstrating significantly greater reductions from baseline in LDL-cholesterol at week 24, compared to placebo or ezetimibe. In the placebo-controlled trials, the average LDL-cholesterol reductions from baseline at week 24 for the Praluent group ranged from 46 to 61 percent. In the ezetimibe-controlled trial with Praluent added to background statins, the average change in LDL-cholesterol from baseline was 51 percent at week 24. In the ezetimibe trials with patients not on statins, the average LDL-cholesterol reduction from baseline in the Praluent group ranged from 45 to 47 percent at week 24. Additionally, significantly more patients achieved an LDL-cholesterol level of less than 70 mg/dL (<1.81 mmol/L) in the Praluent group compared to placebo or ezetimibe at week 12 and week 24.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, September 29, 2015 7:22 PM

Sanofi and Regeneron Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

- Praluent will be available in both a 75 mg and 150 mg dose for self-administration every two weeks -


The ability of Praluent to reduce major CV events is being investigated in the ongoing ODYSSEY OUTCOMES trial, with results anticipated in 2017.  In pre-specified final analyses of the ODYSSEY LONG TERM study, major CV events confirmed by adjudication were reported in 1.7 percent of patients in the Praluent group and 3.3 percent of patients in the placebo group. Hazard ratios were calculated post-hoc; HR=0.52 (95 percent CI, 0.31 to 0.90). In pre-specified analyses of pooled Phase 3 studies, major CV events were reported in 1.6 percent of patients in the Praluent group and 1.8 percent of those in the control group, which included either placebo or ezetimibe (HR=0.81; 95 percent CI, 0.52 to 1.25).

 

Across the Phase 3 trials all-cause mortality was 0.6 percent in the Praluent group and 0.9 percent in the control group, with CV events being the primary cause of death in the majority of these patients.

In clinical trials, Praluent was generally well-tolerated with an acceptable safety profile. Local injection site reactions including erythema/redness, itching, swelling or pain/tenderness where the injection is given were the most common events (6 percent with Praluent versus 4 percent with placebo) in clinical trials. Most injection site reactions were transient and of mild intensity. The discontinuation rate due to local injection site reactions was comparable between the two groups (0.2 percent Praluent and 0.3 percent control groups). Other common adverse events occurring more frequently in the Praluent group than placebo included upper respiratory tract signs and symptoms, and pruritus.

In July, the companies announced that Praluent was approved for use in the U.S. as an adjunct to diet and maximally-tolerated statin therapy for the treatment of adults with HeFH or clinical atherosclerotic CVD (ASCVD), who require additional lowering of LDL-cholesterol. The effect of Praluent on CV morbidity and mortality has not been determined.


Rescooped by Philippe Smelty from Amazing Science
Scoop.it!

Toward tires that repair themselves

Toward tires that repair themselves | Science & Innovation | Scoop.it
A cut or torn tire usually means one thing—you have to buy a new one. But some day, that could change. For the first time, scientists have made tire-grade rubber without the processing step—vulcanization—that has been essential to inflatable tires since their invention. The resulting material heals itself and could potentially withstand the long-term pressures of driving. Their report appears in the journal ACS Applied Materials & Interfaces.

 

Vulcanization involves adding sulfur or other curatives to make rubber more durable while maintaining its elasticity. But once an errant piece of glass or other sharp object pierces a tire, it can't be patched for long-term use. Researchers are beginning to develop self-healing rubber in the laboratory, but these prototypes might not be stable over time either. Amit Das and colleagues wanted to address that shortcoming.


Using a new simple process that avoids vulcanization altogether, the researchers chemically modified commercial rubber into a durable, elastic material that can fix itself over time. Testing showed that a cut in the material healed at room temperature, a property that could allow a tire to mend itself while parked. And after 8 days, the rubber could withstand a stress of 754 pounds per square inch. Heating it to 212 degrees Fahrenheit for the first 10 minutes accelerated the repair process. The researchers say their product could be further strengthened by adding reinforcing agents such as silica or carbon black.


Reference: Ionic Modification Turns Commercial Rubber into a Self-Healing Material, ACS Appl. Mater. Interfaces, 2015, 7 (37), pp 20623–20630 DOI: 10.1021/acsami.5b05041


Via Dr. Stefan Gruenwald
more...
No comment yet.